



November 3, 2006

LIFELINE THERAPEUTICS, INC. "BUILDING BRIDGES TO BETTER HEALTH" NATURAL PRODUCTS NORTHWEST 2006

DENVER, Colorado – Lifeline Therapeutics, Inc. (OTCBB: LFLT), maker of Protandim®, a dietary supplement clinically proven to increase the body's natural antioxidant defenses and to combat oxidative stress, today announced Dr. Sally K. Nelson will speak at Natural Products Northwest 2006.

Dr. Nelson, Lifeline's Science Coordinator, will speak Friday, November 3, 2006. In her presentation, "Protandim®: A Novel Solution to Oxidative Stress", Dr. Nelson will discuss oxidative stress and review the research demonstrating that Protandim® is thousands of times more effective than traditional antioxidants in reducing oxidative stress.

"We are pleased to have Dr. Nelson present at Natural Products Northwest 2006," said Stephen K. Onody, CEO of Lifeline. "The Natural Products Association plays a significant role with the thought leaders in both the natural products industry as well as natural products consumers."

Natural Products Northwest 2006 Tradeshow and Educational Conference takes place November 3 - 5, 2006 in Seattle, Washington.

About Protandim®

Protandim® is a patent-pending dietary supplement that increases the body's natural antioxidant protection by inducing two protective enzymes, superoxide dismutase (SOD) and catalase (CAT). These naturally occurring enzymes simply become overwhelmed by free radicals as we get older. Oxidative stress (cell damage caused by free radicals) occurs as a person ages, when subjected to environmental stresses or as an associated factor in certain illnesses. TBARS are laboratory markers for oxidative stress in the body. Data from a peer-reviewed, published scientific study in men and women, sponsored by Lifeline, show that after 30 days of taking Protandim®, the level of circulating TBARS decreased an average of 40 percent, with this decrease shown to be maintained at 120 days. Protandim® strengthens a person's defenses against oxidative stress by increasing the body's natural antioxidant enzymes. For more information, please visit the Protandim® product web site at www.protandim.com.

About The Natural Products Association (formerly NNFA)

The Natural Products Association is the nation's largest and oldest non-profit organization dedicated to the natural products industry. Its mission is to advocate for the rights of consumers to have access to products that will maintain and improve their health, and for the rights of retailers and suppliers to sell these products. For more information, please visit the association's web site at www.naturalproductsassoc.org.

About Sally K. Nelson, Ph.D.

Dr. Nelson is an Associate Clinical Professor in the Department of Pulmonary and Critical Care Medicine at the University of Colorado at Denver and Health Sciences Center, Denver, Colorado. Dr. Nelson is the Company's Science Coordinator and a shareholder in the Company.

About Lifeline Therapeutics, Inc.

Lifeline Therapeutics, Inc. markets Protandim®. Lifeline Therapeutics is committed to helping people achieve health and wellness for life. For more information, please visit the Company's web site at www.lifelinetherapeutics.com.

Except for historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, applicable common law and Securities and Exchange Commission rules. The Company uses the words "anticipate," "believe," "could," "should," "estimate," "expect," "intend," "may," "predict," "project," "plan," "target" and similar terms and phrases, including references to assumptions, to identify forward-looking statements. These forward-looking statements are based on the Company's current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties are difficult to predict accurately and may be beyond the control of the Company. The following factors

are among those that may cause actual results to differ materially from our forward-looking statements: the Company's ability to successfully expand its operations and manage its future growth; competition in the dietary supplement market; and the Company's dependence on a limited number of significant customers and a single product for revenue. These and other additional risk factors and uncertainties are discussed in greater detail in the Company's Annual Report on Form 10-KSB under the caption "Risk Factors", and in other documents filed the Company from time to time with the Securities and Exchange Commission. Forward-looking statements made by the Company in this news release or elsewhere speak only as of the date made. New uncertainties and risks come up from time to time, and it is impossible for the Company to predict these events or how they may affect the Company. The Company has no duty to, and does not intend to, update or revise the forward-looking statements in this news release after the date it is issued. In light of these risks and uncertainties, investors should keep in mind that the results, events or developments disclosed in any forward-looking statement made in this news release may not occur.

#

CONTACTS:

Lifeline Therapeutics, Inc
Stephen K. Onody, CEO
Phone: 720-488-1711
Gerald J. Houston, CFO
Fax: 303-565-8700